Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 314
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05501717 | Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants | ||
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | ||
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | ||
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | ||
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | ||
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants | ||
| NCT04980248 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | ||
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | ||
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT04551586 | A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants | ||
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT06291376 | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | ||
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults | ||
| NCT00438789 | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol | ||
| NCT02763215 | The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment | ||
| NCT01403389 | A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant | ||
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) | ||
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction | ||
| NCT03346083 | Study Evaluating Betrixaban in Pediatric Participants | ||
| NCT02112994 | Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4) | ||
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | ||
| NCT07557420 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) | ||
| NCT04743804 | Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger | ||
| NCT04594252 | Copper Balance in Healthy Participants Administered ALXN1840 | ||
| NCT01327573 | Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation | ||
| NCT04999020 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | ||
| NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | ||
| NCT07157787 | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | ||
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT01454986 | Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT07413679 | Long-term Safety of Danicopan: IPIG Registry-based Cohort Study | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT04609696 | Study of the Metabolism of Danicopan in Healthy Adults | ||
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | ||
| NCT04623710 | Study of ALXN2050 in Participants With Renal Impairment | ||
| NCT06079359 | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | ||
| NCT03574506 | Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series | ||
| NCT01374360 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | ||
| NCT01522170 | aHUS Observational Long Term Follow-Up | ||
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT01770951 | A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants |
